Mid-June, Mindstrong Health, a startup that uses smartphones to diagnose and treat neuropsychiatric disorders announced that it had secured $14 million in a Series A financial support that was led by various investors among them ARCH Venture Partners, Foresite Capital, One Brain Mind Health Impact Fund, and Optum Ventures. Mindstrong operates a platform that is designed to monitor interaction patterns on smart devices and hence measure the objective cognition of the brain function.
Measuring Cognitive Function Using Smartphone Typing and Scrolling Patterns
In most cases, all modern medicine is based on objective measurement, but mental health has been limited to subjective measures alone. Mindstrong Health, however, wants to improve the outcome of people with mental disorders by using a platform that uses the patients’ smartphone scrolling and typing patterns to measure the brain function. Check out Ideamensch to know more.
By using the program, psychiatrists can get the information on cognition biomarkers which include memory, processing speed, and function. They can also learn about the mood of the patient. According to Dr. Tom Insel, the co-founder, and President of Mindstrong Health, the platform serves as a basis for developing better methods of improving mental health care. The solution is made easy since as mental disorders are global, so are the use of smartphones.
The company carried trial tests and said the results would be released in the coming months. To show his support for the idea, Jim Tananbaum, the CEO of Foresite Capital said the Mindstrong Health founding team had a better understanding of the challenges faced by the medical community when attending to patients with cognitive health disorders.
About Investor Jim Tananbaum
Jim Tananbaum, a graduate of Yale and Harvard, is the founder and CEO of Foresite Capital Management. Jim is associated with several healthcare companies which he has led to success during his 25 years in the industry. Among these enterprises are Jazz Pharmaceuticals, Amira Pharmaceuticals, and Amerigroup.
Before Foresite, Jim founded and managed Theravance and GelTex Pharmaceuticals before Genzyme acquired it for $1.6 billion. At one point, he served on the Harvard-MIT HST program advisory board and also at Yale School of Engineering.
You can visit Foresite Capital’s Facebook page.